Insights Into Renal Cell Carcinoma (RCC) 2025
Perspectives on drivers in treatment decisions in the management of RCC
Southeast – March 22, 2025
Faculty Chair
Jacqueline Brown, MD
Winship Cancer Institute, Atlanta, GA, USA
Texas – June 23, 2025
Faculty Chair
Andrew Hahn, MD
MD Anderson Cancer Center, Houston, TX, USA
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- Texas
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of RCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.